Asymchem (stock code: 002821.SZ) is a leading global CDMO company providing high-quality R&D and one-stop production services for drugs worldwide. Our mission is to accelerate the launch of new drugs through our continuous technological innovation and providing one-stop CMC services for the full lifecycle of drug development for pharmaceutical and biotechnology companies world-wide.
Our solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, fomulations, as well as clinical research services. Through strategic partnerships and calculated business growth, we have built an integrated service ecosystem for innovative drugs and become a global partner in R&D and production for new drugs.
Asymchem's CDMO Solutions
We have been deeply imbedded in the CDMO industry for more than 20 years and continue to promote technological innovation. We are a world leader in flow chemistry and biocatalysis. We have become a long-term partner of some of the world's leading and well-known pharmaceutical companies.
Unprecedented quality system
Our quality management system is one of the best in the world, with a pass rate of 100%. We have successfully passed the audits of government agencies and customers, such as the US FDA, China’s NMPA, TGA from Australia, and MFDS from South Korea.
Well-equipped production capacity
We have a total reaction volume of more than 2,455m³ and the GMP system reaches 1,593m³. The size of the reaction kettle ranges from 1L to 20,000L. With these capacities we are able to meet a variety of clients needs from gram to ton – allowing for rapid start and timely delivery of each project.
IP protection prioritization
Customer information confidentiality is very important to Asymchem and we have established a complete customer information confidentiality system to ensure that customer information is properly protected.